ANDREA RIVERS: Open Payments
NPI 1881050458 · WAYNE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,710 in 21 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $466 · 2025 $1,710
Food & beverage: $1,710
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 4 | $284 |
| Grifols USA, LLC | 4 | $281 |
| ARGENX US, INC. | 2 | $250 |
| Eisai Inc. | 2 | $246 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $173 |
| Lilly USA, LLC | 2 | $150 |
| Genentech USA, Inc. | 1 | $150 |
| Novo Nordisk Inc | 1 | $123 |
| Alexion Pharmaceuticals, Inc. | 1 | $34 |
| Lundbeck LLC | 1 | $18 |
Products named: NUCALA, VYVGART, Leqembi, HYQVIA, Gamunex-C, Ocrevus, Xembify, Ozempic.
Industry payments across NJ — which companies pay providers there.
